Race in a Bottle

Approved by the FDA in 2005 as the first drug with a race-specific indication on its label, BiDil was touted as a pathbreaking therapy to treat heart failure in black patients. Kahn reveals that, at the most basic level, BiDil became racial through legal maneuvering and commercial pressure as much as through medical understandings of how the drug worked. He examines the legal and calls for a more reasoned approach to using race in biomedical research and practice.

Year

2012

Language

English

Publisher

Columbia University Press

Editions

2

Pages

311

ISBN

9780231162982

Data source: Wikidata